S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Germany's Merck to Propose 2-for-1 Stock Split (2014/3/26)|
|Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014 (2014/3/24)|
|FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for Intravenous Use (2014/3/14)|
|Merck Enters Into License Agreement With the Spanish National Cancer Research Centre (CNIO) (2013/12/18)|
|Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies (2014/2/5)|
|Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014 (2014/4/6)|
|Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies (2014/2/5)|
|Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 (2014/2/5)|
|Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ... (2014/3/21)|
|Merck to Hold Third-Quarter 2013 Sales and Earnings Conference Call on October 28 (2013/9/27)|
Click above to view more mutual fund data and stats for merck - Merck Ltd.